GLPG0259: Phase I started

Galapagos began a double-blind, placebo-controlled, multiple ascending-dose, Belgian Phase I trial to evaluate 25, 50 and 75 mg of oral GLPG0259 plus methotrexate for 14 days in 24 healthy volunteers...